keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#1
Jennifer A Dantzer, Robert A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity, and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
January 5, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29315616/in-chronic-spontaneous-urticaria-ige-against-staphylococcal-enterotoxins-is-common-and-functional
#2
S Altrichter, T Hawro, M Liedtke, G Holtappels, C Bachert, P S Skov, M Maurer
BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent disorder with recurrent itchy wheals and/or angioedema. Despite the known effectiveness of omalizumab therapy, the relevant IgE antigens are largely unknown. Recently, increased rates of elevated levels of IgE towards Staphylococcus aureus enterotoxins (SEs) were described in CSU. AIM: To assess the prevalence and functional relevance of IgE to SEs in CSU. METHOD: We investigated serum levels of IgE against SEs in 49 CSU patients and in 15 CSU patients additional specific IgE to SE components and basophil histamine release (BHR)...
January 9, 2018: Allergy
https://www.readbyqxmd.com/read/29300536/autoimmune-polyendocrine-syndrome-type-2-in-patient-with-severe-allergic-asthma-treated-with-omalizumab
#3
Anna Rams, Marek Żółciński, Weronika Zastrzeżyńska, Stanisław Polański, Agnieszka Serafin, Joanna Wilańska, Jacek Musiał, Stanisława Bazan-Socha
Asthma therapy with monoclonal antibodies is a promising and effective approach for those with a severe and refractory type of disease. Although such a targeted therapy is considered to be safe, unusual complications may occur. We present a case of a 45 year-old female patient with severe allergic asthma and chronic spontaneous urticaria, who developed autoimmune polyendocrine syndrome type 2 (APS-2) after 26 months of omalizumab administration. The patient was diagnosed with primary adrenal insufficiency (Addison's disease) and Hashimoto's thyroiditis accompanied by autoimmune atrophic gastritis...
January 4, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29290750/an-update-on-anti-ige-therapy-in-pediatric-respiratory-diseases
#4
REVIEW
Amelia Licari, Riccardo Castagnoli, Elisa Panfili, Alessia Marseglia, Ilaria Brambilla, Gian Luigi Marseglia
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling...
March 2017: Current Respiratory Medicine Reviews
https://www.readbyqxmd.com/read/29290513/efficacy-of-omalizumab-treatment-in-a-man-with-occupational-asthma-and-eosinophilic-granulomatosis-with-polyangioitis
#5
Cristiano Caruso, Giorgia Gencarelli, Francesco Gaeta, Rocco Luigi Valluzzi, Gabriele Rumi, Antonino Romano
No abstract text is available yet for this article.
December 28, 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29288573/omalizumab-treats-chronic-rhinosinusitis-with-nasal-polyps-and-asthma-together-a-real-life-study
#6
T Bidder, J Sahota, C Rennie, V J Lund, D S Robinson, H H Kariyawasam
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma often coexist and thus treating both with one intervention is an attractive strategy. OBJECTIVE: To prospectively evaluate whether treatment with the monoclonal antibody against IgE Omalizumab for severe allergic asthma also effectively treats co-existent CRSwNP. METHODS: SNOT-22 and the ACQ-7 scores were recorded at 4 and 16 weeks of treatment in a cohort of patients with both CRSwNP and severe refractory allergic asthma treated with Omalizumab (n=13) according to UK guidelines for their severe asthma...
December 30, 2017: Rhinology
https://www.readbyqxmd.com/read/29279058/the-effect-of-omalizumab-treatment-on-the-low-affinity-immunoglobulin-e-receptor-cd23-fc-epsilon-rii-in-patients-with-severe-allergic-asthma
#7
Miri Assayag, Shabtai Moshel, Martin Kohan, Neville Berkman
BACKGROUND: Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody used in the treatment of severe asthma. Its therapeutic efficacy is primarily attributed to reduction of serum-free IgE and in the expression of high-affinity IgE receptor, fc epsilon RI. However, its effect on the low-affinity IgE receptor fc epsilon RII/CD23 in vivo has not been evaluated. AIM: To determine whether CD23 plays a role in the inflammatory process in severe uncontrolled asthma and whether anti-IgE therapy modulates fc epsilon RII/CD23 expression in these patients...
January 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29258701/response-to-omalizumab-in-a-patient-with-chronic-eosinophilic-pneumonia-and-poor-response-to-corticosteroids
#8
Eduardo Laviña-Soriano, Ana Ampuero-López, José Luis Izquierdo-Alonso
No abstract text is available yet for this article.
December 16, 2017: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/29249139/omalizumab-for-refractory-chronic-spontaneous-urticaria-during-concurrent-immunomodulatory-therapy-for-multiple-sclerosis
#9
N Syrigos, D Grapsa, E Syrigou
Data derived from previous clinical trials and real-life studies have shown that omalizumab may represent an effective third-line treatment option for patients with chronic spontaneous urticaria (CSU) refractory to standard antihistamine treatment. Nevertheless, the safety and efficacy of omalizumab treatment for CSU, when administered concurrently with other immunomodulatory agents remains largely unknown. We herein present the case of a female patient with relapsing-remitting multiple sclerosis (RRMS), under treatment with interferon beta-1a, azathioprine and gabapentin, who was successfully treated with omalizumab for refractory CSU...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29249138/transient-hair-loss-in-patients-with-chronic-spontaneous-urticaria-treated-with-omalizumab
#10
M Noshela Ghazanfar, S F Thomsen
Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29242014/anti-ige-treatment-with-oral-immunotherapy-in-multifood-allergic-participants-a-double-blind-randomised-controlled-trial
#11
Sandra Andorf, Natasha Purington, Whitney M Block, Andrew J Long, Dana Tupa, Erica Brittain, Amanda Rudman Spergel, Manisha Desai, Stephen J Galli, Kari C Nadeau, R Sharon Chinthrajah
BACKGROUND: Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy benefited multifood allergic patients. METHODS: We did a blinded, phase 2 clinical trial at Stanford University. We enrolled participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges to their offending foods...
December 11, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29238905/biologic-agents-for-severe-asthma-patients-clinical-perspectives-and-implications
#12
REVIEW
Massimo Caruso, Jaymin Morjaria, Rosalia Emma, Maria Domenica Amaradio, Riccardo Polosa
Asthma is a chronic inflammatory multifactorial disorder of the airways characterized by the involvement of immune cells and mediators in its onset and maintenance. Traditional therapeutic strategies have been unsatisfactory in controlling the underlying pathology, especially in the more severe states. Hence in the last couple of decades, new biological approaches targeting molecular mediators have been developed. In this narrative review we examine biological agents currently available for the management of severe asthma, focusing our attention on their clinical application, pros and cons, and in particular on gaps regarding the use of these agents...
December 14, 2017: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/29234969/monoclonal-antibodies-for-treatment-of-eosinophilic-esophagitis
#13
REVIEW
Mahsa Eskian, MirHojjat Khorasanizadeh, Amal H Assa'ad, Nima Rezaei
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting both children and adults, with debilitating and progressive symptoms. EoE has shown an explosive epidemiological rise in the past few decades. Many patients experience a poor level of disease control despite maximal use of available guideline-based therapies, which seriously hampers their quality of life. Diet restrictions and systemic and topical corticosteroids are the current mainstays of EoE therapy, but are associated with significant efficacy, treatment compliance, and safety issues such as oral or esophageal candidiasis, growth retardation, osteopenia, osteoporosis, glucose intolerance, and cataract formation...
December 12, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29234055/oral-immunotherapy-combined-with-omalizumab-for-high-risk-cow-s-milk-allergy-a-randomized-controlled-trial
#14
Masaya Takahashi, Kazuhiko Soejima, Shoichiro Taniuchi, Yasuko Hatano, Sohsaku Yamanouchi, Hideki Ishikawa, Makoto Irahara, Youhei Sasaki, Hiroshi Kido, Kazunari Kaneko
We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow's milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6-14 years) with high IgE levels to CM were enrolled in the present study. Patients were randomized 1:1 to receive OMB-OIT group or untreated group. The primary outcome was the induction of desensitization at 8 weeks after OMB was discontinued in OMB-OIT treated group and at 32 weeks after study entry...
December 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29223296/baseline-asthma-burden-comorbidities-and-biomarkers-in-omalizumab-treated-patients-in-prospero
#15
EDITORIAL
John J Oppenheimer, Paul A Greenberger
No abstract text is available yet for this article.
December 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29213221/omalizumab-in-children-with-severe-allergic-asthma-the-italian-real-life-experience
#16
Amelia Licari, Riccardo Castagnoli, Chiara Denicolò, Linda Rossini, Manuela Seminara, Lucia Sacchi, Giorgia Testa, Mara De Amici, Gian Luigi Marseglia
Background: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled after treatment with high dose of inhaled corticosteroids plus long-acting inhaled beta2-agonist. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies...
March 2017: Current Respiratory Medicine Reviews
https://www.readbyqxmd.com/read/29211611/pregnancy-associated-plasma-protein-a-papp-a-levels-in-patients-with-severe-allergic-asthma-are-reduced-by-omalizumab
#17
Ismet Bulut, Zeynep F Ozseker, Abdurrahman Coskun, Mustafa Serteser, Ibrahim Unsal
BACKGROUND: Remodeling is a crucial feature of severe asthma and may be associated with activation of the allergic cascade by immunoglobulin E (IgE). Omalizumab, an anti-IgE monoclonal antibody, effectively targets the severe allergic asthma phenotype. Pregnancy-associated plasma protein-A (PAPP-A) is an insulin-like growth factor binding protein-4 (IGFBP-4) protease, increasing local insulin-like growth factor (IGF)-1 concentrations, which in turn initiating a cascade involved in the regulation of cell growth, differentiation, and proliferation in various tissues...
December 6, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29208545/il-24-is-a-common-and-specific-autoantigen-of-ige-in-patients-with-chronic-spontaneous-urticaria
#18
Oliver Schmetzer, Elisa Lakin, Fatih A Topal, Patricia Preusse, Denise Freier, Martin K Church, Marcus Maurer
BACKGROUND: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. OBJECTIVE: We sought to identify autoallergic targets of IgE in patients with CSU. METHODS: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins...
December 5, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29208079/asthma-control-lung-function-symptoms-and-corticosteroid-sparing-after-omalizumab-initiation-in-patients-with-allergic-asthma
#19
(no author information available yet)
BACKGROUND: Omalizumab is approved in patients with moderate-to-severe allergic asthma with symptoms uncontrolled, despite the mainstay therapy. OBJECTIVE: Electronic medical records (EMR) were used to increase the knowledge of omalizumab effectiveness in areal-world setting. METHODS: Patients with uncontrolled moderate-to-severe allergic asthma, ages greater than or equal to 12 years old, initiated on omalizumab (index date), with greater than or equal to 12 months of pre- and postindex data, were identified in an EMR data base...
December 5, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29206634/long-term-real-life-safety-of-omalizumab-in-patients-with-severe-uncontrolled-asthma-a-nine-year-study
#20
Danilo Di Bona, Irene Fiorino, Marialuisa Taurino, Flavia Frisenda, Elena Minenna, Carlo Pasculli, Georgios Kourtis, Anna Simona Rucco, Andrea Nico, Marcello Albanesi, Lucia Giliberti, Luciana D'Elia, Maria Filomena Caiaffa, Luigi Macchia
BACKGROUND: Randomized Controlled Trials showed that omalizumab exhibited a good safety and tolerability profile in patients with moderate-to-severe asthma. However, safety data of long-term treatment with omalizumab are scarce. Our aim was to assess the safety of omalizumab in patients under long-term treatment in a real-life setting. METHODS: Difficult-to-control asthmatic patients treated with omalizumab up to 9 years were retrospectively evaluated. Mild to severe adverse events any and reasons for discontinuation were recorded...
September 2017: Respiratory Medicine
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"